EDGEWISE THERAPEUTICS INC
Reported by DEERFIELD MANAGEMENT COMPANY L P SERIES C
Reported 2,874,586 shares, unchanged from the prior quarter.
Reported value -1.3%; share count 0.0% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-12-31 | 60098000 |
| 2022-03-31 | 38151000 |
| 2022-06-30 | 31308000 |
| 2022-09-30 | 38702000 |
| 2022-12-31 | 35162245 |
| 2023-03-31 | 26234024 |
| 2023-06-30 | 30481812 |
| 2023-09-30 | 22536875 |
| 2023-12-31 | 43028519 |
| 2024-03-31 | 52432449 |
| 2024-06-30 | 51771294 |
| 2024-09-30 | 47535050 |
| 2024-12-31 | 55496190 |
| 2025-03-31 | 45727198 |
| 2025-06-30 | 27102565 |
| 2025-09-30 | 12419557 |
| 2025-12-31 | 19000697 |
| 2026-03-31 | 0 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q1 2026 | Reduced | 0 | -765,694 (-100.0%) | 0 | $0 | 2026-05-15 | |
| Q4 2025 | Unchanged | 765,694 | 0 (0.0%) | 0.24% | $19,000,697 | 2026-02-17 | |
| Q3 2025 | Reduced | 765,694 | -1,301,626 (-63.0%) | 0.19% | $12,419,557 | 2025-11-14 | |
| Q2 2025 | Reduced | 2,067,320 | -11,189 (-0.5%) | 0.49% | $27,102,565 | 2025-08-14 | |
| Q1 2025 | Unchanged | 2,078,509 | 0 (0.0%) | 0.9% | $45,727,198 | 2025-05-15 | |
| Q4 2024 | Added | 2,078,509 | +297,503 (16.7%) | 1.05% | $55,496,190 | 2025-02-14 | |
| Q3 2024 | Reduced | 1,781,006 | -1,093,580 (-38.0%) | 0.71% | $47,535,050 | 2024-11-14 | |
| Q2 2024 | Unchanged | 2,874,586 | 0 (0.0%) | 0.86% | $51,771,294 | 2024-08-14 | |
| Q1 2024 | Reduced | 2,874,586 | -1,058,551 (-26.9%) | 0.91% | $52,432,449 | 2024-05-15 | |
| Q4 2023 | Unchanged | 3,933,137 | 0 (0.0%) | 0.79% | $43,028,519 | 2024-02-14 | |
| Q3 2023 | Unchanged | 3,933,137 | 0 (0.0%) | 0.5% | $22,536,875 | 2023-11-14 | |
| Q2 2023 | Unchanged | 3,933,137 | 0 (0.0%) | 0.65% | $30,481,812 | 2023-08-14 | |
| Q1 2023 | Unchanged | 3,933,137 | 0 (0.0%) | 0.58% | $26,234,024 | 2023-05-15 | |
| Q4 2022 | Unchanged | 3,933,137 | 0 (0.0%) | 0.73% | $35,162,245 | 2023-02-14 | |
| Q3 2022 | Unchanged | 3,933,137 | 0 (0.0%) | 0.77% | $38,702,000 | 2022-11-14 | |
| Q2 2022 | Unchanged | 3,933,137 | 0 (0.0%) | 0.65% | $31,308,000 | 2022-08-15 | |
| Q1 2022 | Unchanged | 3,933,137 | 0 (0.0%) | 0.85% | $38,151,000 | 2022-05-16 | |
| Q4 2021 | Unchanged | 3,933,137 | 0 (0.0%) | 1.26% | $60,098,000 | 2022-02-14 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
162 managers reported EDGEWISE THERAPEUTICS INC for Q2 2024.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Unchanged | 15,021,721 | 0 | 5.38% | $270,541,195 | 14 qtrs |
| RA CAPITAL MANAGEMENT L P | Unchanged | 8,909,091 | 0 | 2.12% | $160,452,729 | 2 qtrs |
| Novo Holdings A S | New | 6,344,430 | +6,344,430 | 6.16% | $114,263,184 | 14 qtrs |
| BlackRock Inc | Added | 6,015,711 | +848,705 | < 0.01% | $108,342,955 | 14 qtrs |
| BAKER BROS ADVISORS LP | Unchanged | 5,840,059 | 0 | 1.34% | $105,179,463 | 14 qtrs |
| FMR LLC | Reduced | 4,780,563 | -1,585,161 | < 0.01% | $86,097,933 | 14 qtrs |
| VANGUARD GROUP INC | Added | 4,508,166 | +490,733 | < 0.01% | $81,192,069 | 14 qtrs |
| Frazier Life Sciences Management L P | Added | 3,731,067 | +427,500 | 3.14% | $67,196,517 | 6 qtrs |
| Cormorant Asset Management LP | Unchanged | 3,006,534 | 0 | 3.13% | $54,147,677 | 14 qtrs |
| DEERFIELD MANAGEMENT COMPANY L P SERIES C This report | Unchanged | 2,874,586 | 0 | 0.86% | $51,771,294 | 14 qtrs |
Filing details and methodology As reported
- Report period
- June 30, 2024
- Filed
- August 14, 2024
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 2,874,586
- Shared
- 0
- None
- 0
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.